Literature DB >> 12507567

An experimental infection model for reproduction of calf pneumonia with bovine respiratory syncytial virus (BRSV) based on one combined exposure of calves.

K Tjørnehøj1, A Uttenthal, B Viuff, L E Larsen, C Røntved, L Rønsholt.   

Abstract

Bovine respiratory syncytial virus (BRSV) has been recognised as an important pathogen in calf pneumonia for 30 years, but surprisingly few effective infection models for studies of the immune response and the pathogenesis in the natural host have been established. We present a reproducible experimental infection model for BRSV in 2-5-month-old, conventionally reared Jersey calves. Thirty-four colostrum-fed calves were inoculated once by aerosol and intratracheal injection with BRSV. Respiratory disease was recorded in 91% of the BRSV-inoculated calves, 72% had an accompanying rise in rectal temperature and 83% exhibited >5% consolidation of the lung tissue. The disease closely resembled natural outbreaks of BRSV-related pneumonia, and detection of BRSV in nasal secretions and lung tissues confirmed the primary role of BRSV. Nine mock-inoculated control calves failed to develop respiratory disease. This model is a valuable tool for the study of the pathogenesis of BRSV and for vaccine efficacy studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12507567      PMCID: PMC7126694          DOI: 10.1016/s0034-5288(02)00154-6

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


Introduction

Bovine respiratory syncytial virus (BRSV) was first reported in 1970 in Switzerland (Paccaud and Jacquier, 1970) and has subsequently been identified worldwide as an important pathogen in acute respiratory disease in calves (Baker and Velicer, 1991; Bryson et al., 1978; Larsen, 2000; Uttenthal et al., 1996; Verhoeff and van Nieuwstadt, 1984). Early attempts to experimentally reproduce pneumonia with BRSV had limited success, and the role of BRSV in calf pneumonia could therefore not be verified (Belknap et al., 1995). Thus, Smith et al. (1975) and Castleman et al. (1985) obtained mild clinical disease but very little postmortem evidence of pneumonia following single inoculations of conventionally reared calves, while others only obtained postmortem evidence of BRSV-pneumonia with little or no clinical disease in gnotobiotic calves (Gaddum et al., 1996; Thomas et al., 1984). When inoculating intratracheally and intranasally for four consecutive days, some authors (Ciszewski et al., 1991; Bryson et al., 1983) reproduced moderate to severe signs of respiratory disease as well as consolidated lung tissue, while others only achieved mild signs of BRSV-infection (Kimman et al., 1987; Otto et al., 1996). Thus, even when using this rather heavy inoculation regimen, reproducibility of the disease has been inconsistent. However, disease has recently been reproduced in 2–6-month-old calves by single aerosol inoculations with North-American field isolates of BRSV (West et al., 1999; Woolums et al., 1999). In this study we describe a reliable experimental infection model for BRSV in 2–5-month-old conventionally reared Jersey calves using a European field isolate of BRSV. The results presented in the present paper have been accumulated over several years and support the papers published by West et al. (1999) and Woolums et al. (1999).

Materials and methods

Calves

Five colostrum-deprived (<6 h old) and 41 colostrum-fed (4–14 days old) Jersey bull calves were obtained from two closed dairy herds and transferred to isolation units at Lindholm. Colostrum-deprived calves were fed 175 ml serum from BRSV-antibody-free cattle in an electrolyte solution for 3 days and treated with amoxicillin (Synulox, Pfizer) on day 2 and 3 after birth. From day 4, all calves were fed milk replacer (“Sundkalv, Type 1,” DLG, Denmark) and reared according to normal management procedures for dairy calves. The calves were tested weekly for BRSV-specific IgM and IgG1 antibodies (Uttenthal et al., 2000) to rule out natural BRSV-infection during rearing. They were 7–22 weeks old at inoculation (median value 14 weeks, interquartil range 11–16 weeks), and were free from persistent infection with bovine virus diarrhoea virus (BVDV) (Rønsholt et al., 1996).

Experimental design

Eight experiments were conducted during 24 months (Table 1), one in colostrum-deprived (exp. III) and seven in colostrum-fed (exp. IV, Va, Vb, VI, VIII, IX, and XI) calves. All calves were inoculated on day 0 PI in each individual experiment. A total of 37 calves were inoculated with BRSV and killed on day 2, 4, 6, 7, 8, 15, or 30 post-inoculation (PI), while nine mock-inoculated control calves were killed on day 2, 4, 6, 8, or 15 PI (Table 1).
Table 1

Summary of eight BRSV-infection experimentsA

Inoculumi
Exp. no.
Day of kill
No. of calves
Number of animals with respiratory disease
Clinical signs (number of days)
Number of days with excretion of BRSV
Results from necropsy
Respiratory rate >40 min−1
Rectal temperature >39.3 °C
Extent of lung consolidation (scores 0–5a)
Detection of BRSV antigen (no. of nine sites)
brsvLLFIIIb421/21, 01, 01, 12, 11c 1c
811/146557



ctrLLFa410/100000c
810/102020c



brsvLLFIV422/21, 11, 02, 03, 26, 5
822/25, 43, 45, 54, 46, 0
1522/24, 44, 35, 14, 10, 0
3033/35, 3, 34, 0, 36, 4, 62e, 1e, 1e0, 0, 0



ctrLLFb410/100010d
810/11f0000d
1510/100010d



brsvCCP1Vb633/34, 3, 21, 1, 11, 1, 03, 2, 35, 6, 6
brsvCCP3Va633/32, 2, 12, 2, 02, 0, 23, 3, 27, 5, 4
brsvCCP3VI711/123534
brsvCCP3VIII766/64, 2, 3, 4, 3, 43, 0, 1, 3, 2, 44, 4, 4, 4, 3, 45, 3, 3, 3, 2, 46, 3, 2, 5, 6, 6



brsvCCP3IXh220/20, 00, 00, 01, 10, 0
420/20, 00, 01, 11, 18, 7
622/22, 21, 23, 32, 56, 8
822/22, 60, 33, 43, 40, 2



ctrCCP1210/100000
410/100010
610/100010
810/100010



brsvCCP4XIg643/42, 1, 3, 02, 1, 0, 03, 3, 3, 34, 1, 2, 07, 7, 7, 0

Recordings from seven experiments: clinical signs and BRSV excretion from the nose from day 0 to day 8 PI, and extent of gross pathological changes and BRSV antigen in the lungs at sacrifice. Clinical signs and BRSV excretion are expressed as duration. Detection of antigen displays number of BRSV-positive of nine predetermined sites in the left lung.

Clinical signs and excretion of BRSV from day 0 to day 8 PI and results from necropsy.

Inoculum consisting of lung lavage fluid (LLF) or first, third, or fourth cell culture passage (CCP), BRSV for BRSV and CTR for control.

According to Fig. 1.

Colostrum-deprived calves.

Only one sample tested.

Calves killed on day 30 PI, hence, not comparable with other calves, because of unknown degree of repair processes.

Four or six samples tested.

This control calf had elevated respiratory rate on day 1 PI, presumably as a result of the inoculation procedure.

Respiratory rates were not measured on day 3 PI in this experiment.

Enrofloxacin-treated calves.

The four calves in exp. XI were treated with 2.5 mg enrofloxacin per kg (Baytril, Bayer) from the day before infection until euthanasia on day 6 PI.

Inocula

A 1-month-old, colostrum-deprived calf (calf #2031) was killed on day 6 after inoculation with lung lavage fluid from a naturally BRSV-infected calf with severe pneumonia (Viuff et al., 1996, calf #3). The left lung of calf #2031 was lavaged with 100 ml of Eagles’ minimal essential medium (Glasgow modification) without antibiotics (MEM−), and this lung lavage fluid inoculum (brsvLLF) was snapfrozen in liquid nitrogen in aliquots of 4 ml and kept at −80 °C. Filtered (0.2 μm) extract of lung tissue from calf #2031was cultured in low passage, semi-primary foetal bovine lung cells (FBL) grown in MEM− with 5% foetal bovine serum, and harvested with sterile glass beads between passages. First, third and fourth cell culture passages (brsvCCP1, 3a, 3b, and 4) were frozen at −80 °C in aliquots of 4 ml and used as inoculum (Table 1). Control inocula consisted of lung lavage fluid from healthy, young calves (ctrLLFa and b) or uninfected FBL cells (ctrCCP1). Co-infection of inocula with bacteria and mycoplasmas was excluded by conventional isolation methods. The inocula were cultured on monolayers of calf kidney cells (CK), which were examined for cytopathogenic effect (CPE), and screened for infection with bovine entero virus (BEV), bovine herpes virus 1 (BoHV-1), parainfluenza 3 virus (PI-3V), bovine adeno virus (BAV), mammalian REO viruses (REO), and BVDV by indirect immunofluorescence test (IFT) using pooled virus-specific hyperimmune rabbit- and swine-sera and anti-species conjugates (Dako, Glostrup, Denmark). The presence of bovine corona virus (BCV) was investigated by ELISA (Uttenthal et al., 1996).

Inoculation procedure

The calves were inoculated once by a combination of 10 min aerosol exposure, mostly containing droplets less than 3 μm (Waechtomat inhalator VM 82, Kruuse, Denmark), followed by one intratracheal injection. The aerosol inoculum was diluted to a total of 5 ml in phosphate-buffered saline (PBS) and administered through a mask covering nostrils and mouth. The intratracheal inoculum was diluted to 20 ml in PBS and injected into trachea during provoked heavy inhalation. A dose of 104.6–105.2 TCID50 of BRSV was administered each way to each of the 37 BRSV-infected calves, while the nine control calves received BRSV-negative inoculum. Any possible loss of infectivity during aerosol creation was not measured.

Clinical monitoring and sampling

Groups of control calves and BRSV-infected calves were kept in separated isolation rooms after inoculation, hence, clinical assessment could not be double blind. Respiratory rates, rectal temperatures, and other clinical signs were recorded, and serum samples and nasal swabs collected, daily from the day of inoculation (day 0 PI) until slaughter. Sampling was reduced to nasal swabs and serum samples three times weekly after day 15 PI. Nasal swabs were collected in 0.8 ml MEM including 1 million IU penicillin and 1 g streptomycin per liter (MEM+). The calves were anaesthetised with 30% pentobarbital (1 ml per 6 kg bodyweight) and bled out through Aa. and Vv. axillaris and iliaca externa. The lungs were immediately removed and photographs taken, from which the extent of macroscopic lesions was rated with a score between 0 and 5 according to Fig. 1 . The gross appearance of the pathological changes of the lung tissue, and the amount and nature of the exudate, were evaluated during the postmortem procedure for the two lungs.
Fig. 1

Basis for scoring of extent of lung damage. Score 0 is given to a lung without pathological lesions. (A) Score 1 (1–5%); (B) score 2 (5–15%); (C) score 3 (15–30%); (D) score 4 (30–50%); (E) score 5 (>50%), dorsal aspect; (F) score 5 (>50%), ventral aspect.

Basis for scoring of extent of lung damage. Score 0 is given to a lung without pathological lesions. (A) Score 1 (1–5%); (B) score 2 (5–15%); (C) score 3 (15–30%); (D) score 4 (30–50%); (E) score 5 (>50%), dorsal aspect; (F) score 5 (>50%), ventral aspect. The left lung was lavaged as described above, and lung tissue samples (2 g) were recovered from nine predetermined sites representing the dorsal, medial, and ventral part of the three lobes, for detection of BRSV antigen by ELISA. Lung lavage fluid and lung tissue from the right lung, preferably from consolidated areas, were examined for BRSV by isolation on FBL cell culture. Growth of BRSV was demonstrated by IFT using guinea pig anti-BRSV serum and anti-guinea pig conjugate (Dako, Glostrup, Denmark). Tissue samples from eight predetermined sites in the right lung, trachea, nasal epithelium, ln. tracheobronchalis, tonsil, and spleen were fixed in 10% neutral-buffered formalin. The tissue samples were examined by conventional histological techniques, and the presence of BRSV-antigen was investigated by immunohistochemistry as previously described (Viuff et al., 1996).

BRSV antigen ELISA

Nasal swabs were pre-treated with 5% Triton X-100 (Serva) for 30 min, while lung tissue samples were triturated (Stomacher) in equal amounts of ELISA buffer (0.015 M Na2HPO4, 0.005 M KH2PO4, 0.5 M NaCl, and 0.05% Tween 20, pH 6.8) and centrifuged at 1600 G for 10 min. One standardised positive control was included for every nine samples. Microplates with 96 wells (Maxisorp U96 immunoplate, Nunc, Denmark) were coated with rabbit anti-BRSV hyperimmune serum (1:800) in carbonate buffer (pH 9.6) for 1 h at 37 °C. Between each step, all wells were rinsed three times in ELISA buffer and left for five minutes with a fourth rinse. The steps were duplicate twofold dilution series (100 μl) of the samples (undiluted—1:128), followed first by normal or anti-BRSV guinea pig serum in alternating columns, then by peroxidase-conjugated rabbit anti-guinea pig immunoglobulins (Dako, Glostrup, Denmark), and finally by OPD substrate. The titrated samples were left overnight at 5 °C, while the guinea pig sera (1/200 with 5% normal rabbit serum) and conjugate (1:700) were incubated for 30 min at 37 °C. The substrate reaction was stopped after 10 min at room temperature by adding 1.0 M H2SO4, and the plates were read at OD 492 nm. The titre of a sample was expressed as the highest positive dilution. Dilutions were considered positive if the OD value of the well added anti-BRSV guinea pig serum was >0.100, and the ratio between the OD values of this well and the corresponding negative well added normal guinea pig serum (P/N ratio) was 3 or above.

Serology

Sera from the day of inoculation and the day of slaughter were tested for antibodies against PI-3, BAV, and BCV by ELISA (Uttenthal et al., 1996), as well as for neutralising antibodies against a Danish BRSV field strain. The neutralising BRSV titre was based on neutralisation peroxidase labelling assay (NPLA), and calculated as a 50% endpoint titre (NPLA50).

Other infectious agents

Supernatant of triturated lung tissue was inoculated into CK monolayers, which were examined for CPE during two cell culture passages, followed by IFT for specific viruses as described for inocula. In addition, tissue from the right lung was tested for the presence of PI-3, BAV, and BCV antigen by ELISA (Uttenthal et al., 1996). Moreover, lung-, spleen-, and liver-samples were investigated for aerobic and anaerobic bacteria, and bronchial swabs for mycoplasmas, by conventional isolation methods.

Statistical analysis

Statistical analysis was performed using GraphPad InStat tm (GraphPad Software, San Diego, CA, USA). The differences between the BRSV-inoculated and mock-inoculated calves in Table 4 were tested for statistical significance using Fisher’s exact test, while Spearman’s correlation coefficient was used to investigate correlations between neutralising antibodies and clinical parameters, as well as in-between clinical parameters (Table 3).
Table 4

Prevalence of signs of respiratory disease in colostrum-fed calves which were killed on day 4 PI or later

Number of animals
Percent
BRSV-inoculatedMock-inoculatedBRSV-inoculated (%)Mock-inoculated (%)

Respiratory rates above 40 min−1c29/320/6910
Rectal temperatures above 39.3 °Cd23/320/6720
Excretion of BRSVc29/320/6910
Lung score above 1e24/29a0/6830
BRSV in lung tissuee24/27b0/5b890

Two-tailed P-value <0.0001.

Two-tailed P-value=0.0018.

Two-tailed P-value=0.0003.

The three BRSV-inoculated calves killed on day 30 PI have been excluded due to unknown degree of repair in the lung tissue.

The five BRSV-inoculated calves and the one mock-inoculated calf killed on days 15 and 30 PI have been excluded due to disappearance of BRSV from the lung tissue after day 8 PI.

Table 3

Correlations in-between lung score and peak values for respiratory rate, rectal temperature, and titre in nasal swabs in the 35 BRSV-infected calves which were killed on day 4 PI or later

Sign 1Sign 2r95%-confidence-intervalP

Peak rectal temperaturePeak respiratory rate0.64190.3738–0.8110<0.0001
Peak rectal temperaturePeak titre in nasal swabs0.47390.1393–0.71130.0061
Peak rectal temperatureLung score0.63270.3706–0.8015<0.0001
Peak respiratory ratePeak titre in nasal swabs0.53470.2054–0.75530.0023
Peak respiratory rateLung score0.47010.1408–0.7050.0058
Peak titre in nasal swabsLung score0.3284−0.03377–0.61430.0665

Results

Baselines for recording of clinical signs and pathological changes were determined from the 6–21-week-long monitoring of the 46 calves before inoculation, and from the findings in the nine control calves after mock-inoculation, respectively. The baselines were set at a respiratory rate of 40 per minute, a rectal temperature of 39.3 °C and 5% consolidation of the lung tissue. Number of days with clinical signs and nasal excretion of BRSV between day 0 and 8 PI are summarised in Table 1.

Mock-inoculated control calves

Except for a febrile reaction and a lung score of 2 in one control calf in exp. III and one control calf with a respiratory rate of 52 on day 1 PI in exp. IV, there were no signs of disease in the mock-inoculated control animals (Table 1). Daily nasal swabs were free from BRSV antigen, and lung tissue samples were free from BRSV antigen and live BRSV.

BRSV-inoculated calves

Respiratory disease was induced in all of the eight experiments (Table 1), as the majority of the BRSV-infected animals in each experiment (67–100%) developed respiratory rates above 40 min−1 for 1–5 days between day 4 and 8 PI, which in 67–100% of the sick animals was accompanied by febrile reactions. BRSV excretion, demonstrated as antigen in nasal swabs, was found in 67–100% of the BRSV-infected calves in each of the experiments (Table 1 ). Summary of eight BRSV-infection experimentsA Recordings from seven experiments: clinical signs and BRSV excretion from the nose from day 0 to day 8 PI, and extent of gross pathological changes and BRSV antigen in the lungs at sacrifice. Clinical signs and BRSV excretion are expressed as duration. Detection of antigen displays number of BRSV-positive of nine predetermined sites in the left lung. Clinical signs and excretion of BRSV from day 0 to day 8 PI and results from necropsy. Inoculum consisting of lung lavage fluid (LLF) or first, third, or fourth cell culture passage (CCP), BRSV for BRSV and CTR for control. According to Fig. 1. Colostrum-deprived calves. Only one sample tested. Calves killed on day 30 PI, hence, not comparable with other calves, because of unknown degree of repair processes. Four or six samples tested. This control calf had elevated respiratory rate on day 1 PI, presumably as a result of the inoculation procedure. Respiratory rates were not measured on day 3 PI in this experiment. Enrofloxacin-treated calves. Clinical signs and virus shedding were accompanied by enhanced vesicular or bronchial respiration, nasal discharge, coughing, and varying degrees of anorexia and depression (data not shown). Temporal development in average respiratory rates and in average rectal temperatures from inoculation to slaughter are shown for calves inoculated with lung lavage fluid based inocula in Fig. 2I and for calves inoculated with cell culture passaged inocula in Fig. 2II. For clarity, data have been pooled for experiments using brsvCCP3 (Va, VI, VIII, and IX). Both lung lavage BRSV-inoculum and cell culture passaged BRSV-inocula induced increases in average respiratory rates and average rectal temperatures on day 4–6 PI; accordingly the two BRSV-inoculated calves killed on day 2 PI did not show any signs of respiratory disease. Average rectal temperatures returned to normal levels around day 8–9 PI, while average respiratory rate remained high until day 13 PI (based on five calves).
Fig. 2

Temporal development in average respiratory rate (per minute) and average rectal temperature (°C) after inoculation of calves with lung lavage fluid-based (I) or cell culture passaged (II) BRSV- or mock-inoculum. Graphs display 95%-confidence-intervals. 95%-confidence-intervals are not applicable in cases with one animal per group. Baselines indicated in solid at 40 respirations/min and 39.3 °C, respectively. (I) Colostrum-deprived calves (exp. III) inoculated with brsvLLF (♦) or ctrLLF (♢). Colostrum-fed calves (exp. IV) inoculated with brsvLLF (■) or ctrLLF (□). (II) Colostrum-fed calves inoculated with brsvCCP1 (exp. Vb) (•), brsvCCP3 (exp. Va, VI, VIII, and IX) (▴), brsvCCP4 (exp. XI) (×), or ctrCCP1 (exp. IX) (▵).

Temporal development in average respiratory rate (per minute) and average rectal temperature (°C) after inoculation of calves with lung lavage fluid-based (I) or cell culture passaged (II) BRSV- or mock-inoculum. Graphs display 95%-confidence-intervals. 95%-confidence-intervals are not applicable in cases with one animal per group. Baselines indicated in solid at 40 respirations/min and 39.3 °C, respectively. (I) Colostrum-deprived calves (exp. III) inoculated with brsvLLF (♦) or ctrLLF (♢). Colostrum-fed calves (exp. IV) inoculated with brsvLLF (■) or ctrLLF (□). (II) Colostrum-fed calves inoculated with brsvCCP1 (exp. Vb) (•), brsvCCP3 (exp. Va, VI, VIII, and IX) (▴), brsvCCP4 (exp. XI) (×), or ctrCCP1 (exp. IX) (▵). After day 4 PI, the average rectal temperature in brsvLLF-inoculated calves (Figs. 2I and B) was higher in the remaining colostrum-deprived calf than in the colostrum-fed calves (seven calves); however, two of the colostrum-fed calves had as severe febrile reactions as the colostrum-deprived calf. This situation illustrates the effect of the variation in time of onset (1–2 days) and in severity of clinical disease between individual calves on the average values. As a consequence we have also considered the individual peak respiratory rate, peak rectal temperature and peak titre of BRSV in nasal swabs in the 35 BRSV-infected calves which were killed on day 4 PI and later (Table 2 ). Median values were 72 min−1 for peak respiratory rate, 39.9 °C for peak rectal temperature, and 64 (26) for peak titre of BRSV in nasal swabs. Peak rectal temperature correlated with peak respiratory rate, peak titre in nasal swabs and lung score, and peak respiratory rate correlated with peak titre in nasal swabs and lung score, while peak titre in nasal swabs did not correlate significantly with lung score (Table 3 ).
Table 2

Peak values for signs of respiratory disease in the 35 BRSV-infected calves which were killed on day 4 PI or later

Sign ofRangeMedian valueInterquartil range

Peak respiratory rate24–104 min−172 min−154–84 min−1
Peak rectal temperature38.5–41.1 °C39.9 °C39.2–40.4 °C
Peak titre in nasal swab<1 (20)–128 (27)64 (26)8–128 (23–27)
Peak values for signs of respiratory disease in the 35 BRSV-infected calves which were killed on day 4 PI or later Correlations in-between lung score and peak values for respiratory rate, rectal temperature, and titre in nasal swabs in the 35 BRSV-infected calves which were killed on day 4 PI or later Substantial pneumonic lesions, manifested as lobular, dark red, consolidated areas with mucopurulent exudate in the bronchi, were typically detected in the cranio-ventral parts of the lungs from day 4 PI in BRSV-inoculated calves (Table 1). Thus, moderate to severe lung consolidation (lung scores 2 or above) was present in 0/2 calves killed on day 2 PI (0%), 3/6 killed on day 4 PI (50%), 22/24 killed on days 6–8 PI (92%), 1/2 killed on day 15 PI (50%), and 1/3 killed on day 30 PI (33%). Interstitial oedema was seen in most BRSV-infected calves, whereas emphysema was seen in animals killed on day 6 and 8 PI. The emphysema was especially pronounced in the caudal lobes, and less frequently seen in the medial and accessory lobes. The incidence of emphysema rose with increasing lung score; lung score 0–2: 0/18 (0%), lung score 3: 2/10 (20%), lung score 4: 3/6 (50%), and lung score 5: 3/3 (100%) (data not shown). A detailed description of the replication and clearance of BRSV in these calves is given elsewhere (Viuff et al., accepted). Immunohistochemistry revealed BRSV antigen in a few scattered bronchial epithelial cells in calves killed on day 2 PI, and in a high number of bronchial epithelial cells on day 4 PI. Large amounts of BRSV antigen were found in bronchiolar and alveolar epithelial cells on day 6–8 PI (Fig. 3 ). The pathological lesions were clearly associated with the presence of BRSV as a shift in the main lesions from bronchitis to bronchiolitis and alveolitis was observed corresponding to the sites where BRSV was detected. BRSV antigen was not detected in lung tissue samples from calves killed on days 15 and 30 PI or from mock-inoculated control calves.
Fig. 3

BRSV antigen demonstrated by immunohistochemistry in a BRSV infected calf killed PID 6 (antigen positive cells are red). (A) High amount of BRSV antigen is detected in alveolar epithelial cells (exemplified by arrowheads) and in the epithelial cells of a bronchiole (b). Also the cellular exudate in the bronchiole is containing BRSV antigen. (B) A high number of BRSV antigen containing syncytial cells is demonstrated PID 6. (C) Emphysema located in an area with BRSV antigen.

BRSV antigen demonstrated by immunohistochemistry in a BRSV infected calf killed PID 6 (antigen positive cells are red). (A) High amount of BRSV antigen is detected in alveolar epithelial cells (exemplified by arrowheads) and in the epithelial cells of a bronchiole (b). Also the cellular exudate in the bronchiole is containing BRSV antigen. (B) A high number of BRSV antigen containing syncytial cells is demonstrated PID 6. (C) Emphysema located in an area with BRSV antigen. The microscopical lesions were characteristic for BRSV-related pneumonia featuring formation of syncytial cells, hyperplasia of bronchial epithelium with loss of cilia, influx of neutrophils, plugging of bronchi, bronchioles, and alveoli, collapse of alveoli, interstitial oedema, and emphysema (Fig. 3). From day 15 PI the overall impression was repair. The antigen ELISA detected BRSV in lung tissue from 24/25 animals killed between day 4 and 7 PI and from 3/5 calves killed on day 8 PI, while lung tissue samples from calves killed on days 2, 15, and 30 PI were negative (Table 1). Antigen titres in the 143 BRSV-positive lung samples (Table 1) ranged between 2 and >128 (21 to >27) (median value 64 (26), interquartil range 32–128 (25–27)). Detection of BRSV by isolation on FBL cells preceded detection of antigen by ELISA, while the ELISA demonstrated BRSV later in the course of the infection. The results from the 39 colostrum-fed calves, which were killed on day 4 PI or later, have been summarised in Table 4 . A total of 91% of BRSV-inoculated calves (29/32) developed respiratory rates above 40 min−1, 72% (23/32) had febrile reactions and 91% (29/32) excreted BRSV. Animals killed on day 30 PI have been excluded from lung score due to unknown degree of repair, and animals killed on day 15 and 30 PI from BRSV in lung tissue due to disappearance of antigen after day 8 PI. Thus 83% (24/29) had lung scores above 1 and 89% (24/27) contained BRSV antigen in the lung tissue at slaughter. In contrast, none of the mock-inoculated calves exhibited signs of disease after inoculation. Using Fisher’s exact test all five parameters were significantly more prevalent in the BRSV-inoculated calves as compared to the mock-inoculated calves (two-tailed P-value <0.005). Prevalence of signs of respiratory disease in colostrum-fed calves which were killed on day 4 PI or later Two-tailed P-value <0.0001. Two-tailed P-value=0.0018. Two-tailed P-value=0.0003. The three BRSV-inoculated calves killed on day 30 PI have been excluded due to unknown degree of repair in the lung tissue. The five BRSV-inoculated calves and the one mock-inoculated calf killed on days 15 and 30 PI have been excluded due to disappearance of BRSV from the lung tissue after day 8 PI. The colostrum-deprived calves were free from neutralising BRSV-specific antibodies at the time of inoculation, while the colostrum-fed calves had varying levels of maternally derived neutralising antibodies (range <2–362 NPLA50, median value 91 NPLA50, interquartil range 10–256 NPLA50). However, the neutralising antibody titre at inoculation did not correlate with peak respiratory rate (r=−0.002765, 95%-confidence-interval: −0.4000–0.3953, two-tailed P-value=0.6060), peak rectal temperature (r=0.1475, 95%-confidence-interval: −0.2497–0.5022, two-tailed P-value=0.4537) or lung score (r=0.08926, 95%-confidence-interval: −0.2904–0.4446, two-tailed P-value=0.6390) in BRSV-inoculated, colostrum-fed calves. Low neutralising titres tended to rise from day 6 PI, while calves with a higher pre-infection titre generally showed a decrease in titre. The neutralising antibody response appeared to develop slightly earlier (Tjørnehøj, 2000) than the IgG1 response, which is described by Uttenthal et al. (2000). All cell culture based inocula (exp. V–XI) were free from interfering bovine pathogens. In contrast, the lung lavage fluid inocula (brsvLLF, ctrLLFa, and ctrLLFb) were infected with Mycoplasma dispar (exp. III and IV), and ctrLLFa was infected with BCV (exp. III). At postmortem, bronchial swabs from 67% of the control calves and from 78% of the BRSV-inoculated calves contained M. dispar, while the corresponding figures for Ureaplasma spp. were 33% and 38%. Mycoplasma bovirhinis was recovered from one control and two BRSV-inoculated calves, while three BRSV-infected calves had Pasteurella multocida, one Pasteurella avium, and two Haemophilus somnus in the lung tissue. In experiment III, all five calves excreted BCV, which was also detected in lung tissue from calves killed on day 4 PI. Sero-conversions to PI-3, BCV, or BAV were not detected in any of the calves.

Discussion

In this study, moderate to severe BRSV-induced pneumonia was reproduced in seven experiments in colostrum-fed calves and in one experiment in colostrum-deprived calves. Nasal shedding of BRSV and recovery of BRSV from the lungs at necropsy, in particular the constant demonstration of BRSV antigen in affected lung tissue from BRSV-infected calves by immunohistochemistry, confirmed that this virus caused the disease. The described experimental BRSV-infections were confined to the respiratory system as demonstrated in a previously published systematic screening of other tissues for BRSV by RT-PCR, however, BRSV-specific RNA was detected in the tracheobronchal lymph node from some of the calves killed between day 2 and 6 PI (Larsen et al., 1999). The severity of the elicited parameters of respiratory disease varied amongst individual calves, but the peak values of respiratory rate, rectal temperature, and titre of BRSV in nasal swabs were significantly correlated with each other, and the peak respiratory rate and rectal temperature correlated significantly with lung score. Likewise, emphysema, a sign of severe respiratory distress, was only noted in severely affected calves. Thus, it is verified that the measured parameters of respiratory disease were associated with each other and caused by the BRSV-infection. The variation amongst individual animals was comparable between our individual experiments. This disease pattern, the clinical signs and the distribution and character of lung lesions in the BRSV-inoculated calves equalled descriptions of BRSV-related pneumonia in naturally infected calves (Belknap, 1993; Bryson, 1993; Kimman et al., 1989; Pirie et al., 1981; Verhoeff and van Nieuwstadt, 1984; Verhoeff et al., 1984; Viuff et al., 1996). The severity of elicited pneumonia did not correlate to the level of maternally derived neutralising antibodies at inoculation; and after the successful inoculation of colostrum-fed calves in experiment IV, we decided to focus on this type of calves to establish a more natural experimental model. Only 2/6 BRSV-inoculated calves killed on day 4 PI had signs of disease, but, since lung tissue samples of all six calves were positive for BRSV by both isolation and antigen ELISA, they were probably incubating the disease. Consistently, the two healthy BRSV-inoculated calves killed on day 2 PI had a few BRSV-infected bronchial epithelial cells. The acute phase of the infection, manifested by nasal virus excretion, febrile reaction, and presence of viral antigen in the lungs, had almost ended by day 8 PI, while nasal discharge, coughing and consolidation of lung tissue persisted until day 15 and 30 PI in some animals, indicating a prolonged reparatory state in the lung tissue. According to the average respiratory rates presented in Fig. 2, enhanced respiratory rates seemed to cease around day 13–15 PI. However, one of the three calves killed on day 30 PI maintained enhanced respiratory rate until this day, and more recent experimental BRSV-infections using our model has confirmed long-term respiratory distress in some of the infected animals (unpublished data). The degree of respiratory disease achieved in these experiments was more distinct than in most previous studies using single inoculation of conventionally reared calves (Belknap et al., 1995). However, Elazhary et al. (1980), West et al. (1999), and Woolums et al. (1999) have obtained comparable levels of clinical signs with one inoculation. One common factor between these three successful studies and the present model is the exposure to BRSV in an aerosol delivered by a nebulizer over an extended period of time, and we believe this has been crucial for the induction of disease. The exact mode of transmission during a natural BRSV-infection has not yet been unambiguously defined. It has been demonstrated that the human RSV virus is probably very commonly transferred by contact spread of large droplets between high-risk patients in hospitals (Hall and Douglas, 1981), while Mars et al. (1999) recently demonstrated experimentally that BRSV can be transmitted by air between groups of calves in adjacent rooms. The pathological lesions seen after the combined aerosol and intratracheal exposure in the present study closely resembled the pathological lesions in acute BRSV-related pneumonia in the field (Bryson, 1993; Kimman et al., 1989; Pirie et al., 1981; Viuff et al., 1996); moreover, the infection progressed from the upper to the lower respiratory tract during 4–6 days (Viuff et al., accepted). Taken together, these findings indicate that the inoculation with aerosol for 10 min is probably quite close to the field exposure, where calves due to the close housing are continuously exposed to BRSV during an outbreak. In experiment III, mock-inoculated and BRSV-inoculated calves experienced a co-infection with BCV, which presumably originated from the BCV-infected mock-inoculum and reached the BRSV-inoculated calves through the contaminated inhalator. This infection probably caused the slightly higher rectal temperature in the colostrum-deprived control calf on day 4–8 PI, and it may also have influenced the rectal temperature of the colostrum-deprived, BRSV-inoculated calf (Figs. 2I and B). However, due to the limited number of animals in this experiment, this is merely a speculation. Pasteurella multocida, P. avium, and H. somnus were infrequently recovered from BRSV-inoculated calves, while mycoplasmas were isolated from most BRSV-inoculated calves as well as from control calves in the present study, indicating that the calves were harbouring mycoplasmas at the time of infection. However, there was no clear correlation between degree of respiratory disease and recovery of bacteria, as bacteria could be found in both animals with widespread and limited extent of lung consolidation, and some calves without bacterial infection displayed serious lung lesions. Moreover, respiratory disease was also induced in the enrofloxacin-treated calves in exp. XI. The interfering bacterial and mycoplasmal airway pathogens in this study are also commonly recovered from the respiratory system of healthy calves (Thomas and Smith, 1972; Woldehiwet et al., 1990a; Woldehiwet et al., 1990b); essentially Woldehiwet et al. (1990b) were unable to associate isolation rates of mycoplasmas with respiratory disease in calves. Besides, the character of the induced pneumonias in the present study differ from those recorded in experimental infection studies with H. somnus (Jackson et al., 1987), P. multocida (Gourlay et al., 1989), and mycoplasmas (Friis, 1980; Friis, 1981; Howard et al., 1976; Tanskanen, 1984). Hence, though it cannot be ruled out that bacteria or mycoplasmas may have played a contributing role in the clinical course of the disease, the combination of cell culture based inoculum and thorough examination of inocula as well as experimental calves for other bovine pathogens made it possible to exclude that they played a primary etiological role in the present study. Thus, we have by consistent experimental reproduction of moderate to severe disease clearly demonstrated the capability of BRSV as a primary etiologic agent of acute pneumonia in calves. On day 2 PI, BRSV could only be detected in the lung tissue by immunohistochemistry, PCR (Larsen et al., 1999) and isolation, indicating that these methods were more sensitive than the presented antigen ELISA. However, the ELISA detected BRSV later in the course of infection than the isolation method, in lung tissue as well as in nasal swabs (Tjørnehøj, 2000). Whether this was caused by the presence of neutralising antibodies or other inhibiting immunological factors, or by the die off of the BRSV particles, leaving antigen for a few more days, is not known. In conclusion, we have established a reproducible experimental model for BRSV-infection using a Danish field strain of BRSV. This model was capable of inducing clinical signs resembling natural cases of BRSV-related pneumonia in 80% of the infected conventionally reared calves, and hence mimics the field conditions closely. Consequently, it may be a valuable tool for studying the pathogenesis of BRSV-infection and for vaccine efficacy studies. Studies on these issues have been published elsewhere (Heegaard et al., 2000; Larsen et al., 1998; Larsen et al., 1999; Røntved et al., 2000; Uttenthal et al., 2000; Viuff et al., accepted).
  38 in total

1.  Induction of pneumonia in gnotobiotic calves following inoculation of Mycoplasma dispar and ureaplasmas (T-mycoplasmas).

Authors:  C J Howard; R N Gourlay; L H Thomas; E J Stott
Journal:  Res Vet Sci       Date:  1976-09       Impact factor: 2.534

2.  Experimental Pasteurella multocida pneumonia in calves.

Authors:  R N Gourlay; L H Thomas; S G Wyld
Journal:  Res Vet Sci       Date:  1989-09       Impact factor: 2.534

3.  Evaluation of severe disease induced by aerosol inoculation of calves with bovine respiratory syncytial virus.

Authors:  A R Woolums; M L Anderson; R A Gunther; E S Schelegle; D R LaRochelle; R S Singer; G A Boyle; K E Friebertshauser; L J Gershwin
Journal:  Am J Vet Res       Date:  1999-04       Impact factor: 1.156

4.  Acute fatal pneumonia in calves due to respiratory syncytial virus.

Authors:  H M Pirie; L Petrie; C R Pringle; E M Allen; G J Kennedy
Journal:  Vet Rec       Date:  1981-05-09       Impact factor: 2.695

5.  Pathogenesis of naturally acquired bovine respiratory syncytial virus infection in calves: morphologic and serologic findings.

Authors:  T G Kimman; P J Straver; G M Zimmer
Journal:  Am J Vet Res       Date:  1989-05       Impact factor: 1.156

6.  Viral aetiology of enzootic pneumonia in Danish dairy herds: diagnostic tools and epidemiology.

Authors:  A Uttenthal; N P Jensen; J Y Blom
Journal:  Vet Rec       Date:  1996-08-03       Impact factor: 2.695

7.  Respiratory syncytial virus pneumonia in young calves: clinical and pathologic findings.

Authors:  D G Bryson; M S McNulty; E F Logan; P F Cush
Journal:  Am J Vet Res       Date:  1983-09       Impact factor: 1.156

8.  Experimental Haemophilus somnus pneumonia in calves.

Authors:  J A Jackson; J J Andrews; J W Hargis
Journal:  Vet Pathol       Date:  1987-03       Impact factor: 2.221

9.  Replication and clearance of respiratory syncytial virus: apoptosis is an important pathway of virus clearance after experimental infection with bovine respiratory syncytial virus.

Authors:  Birgitte Viuff; Kirsten Tjørnehøj; Lars E Larsen; Christine M Røntved; Ase Uttenthal; Leif Rønsholt; Soren Alexandersen
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

10.  A model for respiratory syncytial virus (RSV) infection based on experimental aerosol exposure with bovine RSV in calves.

Authors:  P Otto; M Elschner; P Reinhold; H Köhler; H J Streckert; S Philippou; H Werchau; K Morgenroth
Journal:  Comp Immunol Microbiol Infect Dis       Date:  1996-02       Impact factor: 2.268

View more
  12 in total

1.  Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine.

Authors:  M Oumouna; J W Mapletoft; B C Karvonen; L A Babiuk; S van Drunen Littel-van den Hurk
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

Review 2.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

3.  DNA immunization with plasmids encoding fusion and nucleocapsid proteins of bovine respiratory syncytial virus induces a strong cell-mediated immunity and protects calves against challenge.

Authors:  Mathieu Boxus; Marylène Tignon; Stefan Roels; Jean-François Toussaint; Karl Walravens; Marie-Ange Benoit; Philippe Coppe; Jean-Jacques Letesson; Carine Letellier; Pierre Kerkhofs
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

4.  ITIH4 (inter-alpha-trypsin inhibitor heavy chain 4) is a new acute-phase protein isolated from cattle during experimental infection.

Authors:  M Piñeiro; M Andrés; M Iturralde; S Carmona; J Hirvonen; S Pyörälä; P M H Heegaard; K Tjørnehøj; F Lampreave; A Piñeiro; M A Alava
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

5.  Replication and clearance of respiratory syncytial virus: apoptosis is an important pathway of virus clearance after experimental infection with bovine respiratory syncytial virus.

Authors:  Birgitte Viuff; Kirsten Tjørnehøj; Lars E Larsen; Christine M Røntved; Ase Uttenthal; Leif Rønsholt; Soren Alexandersen
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

6.  A bovine respiratory syncytial virus model with high clinical expression in calves with specific passive immunity.

Authors:  Krister Blodörn; Sara Hägglund; Dolores Gavier-Widen; Jean-François Eléouët; Sabine Riffault; John Pringle; Geraldine Taylor; Jean François Valarcher
Journal:  BMC Vet Res       Date:  2015-03-25       Impact factor: 2.741

7.  Bovine respiratory syncytial virus ISCOMs-Immunity, protection and safety in young conventional calves.

Authors:  Sara Hägglund; Kefei Hu; Karin Vargmar; Lesly Poré; Ann-Sophie Olofson; Krister Blodörn; Jenna Anderson; Parvin Ahooghalandari; John Pringle; Geraldine Taylor; Jean-François Valarcher
Journal:  Vaccine       Date:  2011-08-22       Impact factor: 3.641

8.  Bovine respiratory syncytial virus infection enhances Pasteurella multocida adherence on respiratory epithelial cells.

Authors:  Putu Eka Sudaryatma; Kimika Nakamura; Hirohisa Mekata; Satoshi Sekiguchi; Meiko Kubo; Ikuo Kobayashi; Mawar Subangkit; Yoshitaka Goto; Tamaki Okabayashi
Journal:  Vet Microbiol       Date:  2018-04-30       Impact factor: 3.293

9.  A single vaccination with an inactivated bovine respiratory syncytial virus vaccine primes the cellular immune response in calves with maternal antibody.

Authors:  Mirjam T W van der Sluijs; Eva M Kuhn; Birgit Makoschey
Journal:  BMC Vet Res       Date:  2010-01-11       Impact factor: 2.741

10.  Vaccination of calves using the BRSV nucleocapsid protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects the lungs against BRSV replication and pathology.

Authors:  Carine Letellier; Mathieu Boxus; Laurent Rosar; Jean-François Toussaint; Karl Walravens; Stefan Roels; Gilles Meyer; Jean-Jacques Letesson; Pierre Kerkhofs
Journal:  Vaccine       Date:  2008-07-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.